Referred Tests
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing. | |
Test ID: PGN
Pregabalin, Serum
Useful For 
Suggests clinical disorders or settings where the test may be helpful
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Pregabalin (Lyrica) is an anticonvulsant drug used to treat partial seizures in patients and is a more potent successor to gabapentin. Pregabalin is commonly used for neuropathic pain and fibromyalgia. This test can be used by physicians to assess compliance and may be clinically useful in patients with renal failure who generally require lower dosages. Therapeutic and toxic ranges are not well defined. Therapeutic concentrations are reported to be from 2 to 5 mcg/mL, while toxicity may occur at concentrations above 10 mcg/mL.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
2.0-5.0 mcg/mL
Interpretation Provides information to assist in interpretation of the test results
The serum concentration should be interpreted in the context of the patient's clinical response and other clinical tests. This may provide useful information in patients showing poor response, noncompliance, or adverse effects. Toxicity can occur with concentrations greater or equal to 10 mcg/mL.
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
This test cannot be performed on whole blood.
Clinical Reference Recommendations for in-depth reading of a clinical nature
1. Baselt R: Disposition of Toxic Drugs and Chemicals in Man. 10th ed. Biomedical Publications; 2014
2. Hiemke C, Bergemann N, Clement HW, et al: Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018;51:9-62